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Aims To test whether N-terminal pro-B-type natriuretic peptide (NT-proBNP) was independently associated with, and
improved the prediction of, cardiovascular disease (CVD) in a primary prevention cohort.
Methods
and results
In the West of Scotland Coronary Prevention Study (WOSCOPS), a cohort of middle-aged men with hypercholes-
terolaemia at a moderate risk of CVD, we related the baseline NT-proBNP (geometric mean 28 pg/mL) in 4801
men to the risk of CVD over 15 years during which 1690 experienced CVD events. Taking into account the competing
risk of non-CVD death, NT-proBNP was associated with an increased risk of all CVD [HR: 1.17 (95% CI: 1.11–1.23)
per standard deviation increase in log NT-proBNP] after adjustment for classical and clinical cardiovascular risk factors
plus C-reactive protein. N-terminal pro-B-type natriuretic peptide was more strongly related to the risk of fatal [HR:
1.34 (95% CI: 1.19–1.52)] than non-fatal CVD [HR: 1.17 (95% CI: 1.10–1.24)] (P ¼ 0.022). The addition of NT-
proBNP to traditional risk factors improved the C-index (+0.013; P, 0.001). The continuous net reclassification
index improved with the addition of NT-proBNP by 19.8% (95% CI: 13.6–25.9%) compared with 9.8% (95% CI:
4.2–15.6%) with the addition of C-reactive protein. N-terminal pro-B-type natriuretic peptide correctly reclassified
14.7% of events, whereas C-reactive protein correctly reclassified 3.4% of events. Results were similar in the 4128
men without evidence of angina, nitrate prescription, minor ECG abnormalities, or prior cerebrovascular disease.
Conclusion N-terminal pro-B-type natriuretic peptide predicts CVD events in men without clinical evidence of CHD, angina, or
history of stroke, and appears related more strongly to the risk for fatal events. N-terminal pro-B-type natriuretic
peptide also provides moderate risk discrimination, in excess of that provided by the measurement of C-reactive
protein.
Clinical trial
registration
WOSCOPS was carried out and completed prior to the requirement for clinical trial registration.
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Introduction
A recent meta-analysis of 40 prospective studies suggests that both
B-type natriuretic peptide (BNP) and the inactive N-terminal frag-
ment of proBNP (NT-proBNP) are associated with the cardiovas-
cular disease (CVD) risk, such that there was a three-fold
increased risk in those with natriuretic peptide levels in the top
third after controlling for confounders.1 Despite the strong associ-
ation with risk of CVD, the potential clinical utility of natriuretic
peptides in risk scores remains uncertain. It is possible that the
utility of natriuretic peptides in predicting CVD events is largely
restricted to the identification of those who have pre-existing clin-
ical, or subclinical, CVD. Indeed natriuretic peptides are associated
with previous silent infarcts.2– 4 Studies evaluating the predictive
performance of natriuretic peptides among individuals free of
overt CVD are sparse. Overall, these studies have shown
minimal or only modest increases in discrimination and reclassifica-
tion, although statistical power has been limited.5– 9 Such studies
have also generally been unable to adjust or stratify for subclinical
cardiac disease.
The West of Scotland Coronary Prevention Study (WOSCOPS)
involved a primary prevention cohort of hypercholesterolaemic
middle-aged men at moderate CVD risk. Using WOSCOPS, we
sought to relate NT-proBNP to the risk of CVD events and all-
cause mortality in the entire cohort and in a subset without evi-
dence of ischaemia or minor significant ECG abnormalities. We
assessed whether NT-proBNP improved the prediction CVD
compared with C-reactive protein.
Methods
WOSCOPS participants
The design and recruitment of WOSCOPS has been reported
elsewhere.10 –14 Briefly, 6595 moderately hypercholesterolaemic
men (serum LDL-cholesterol 4.5–6.0 mmol/L and triglycerides
,6.0 mmol/L) with no history of myocardial infarction (MI) were rando-
mized to pravastatin 40 mg daily or placebo and followed initially for an
average of 4.9 years. All subjects provided written informed consent and
ethical approval was obtained. Men attended the screening clinic (pre-
randomization to pravastatin/placebo) fasted and had plasma samples
taken. A range of physical and biochemical CVD risk factors and other
demographic variables was assessed at baseline.10–14 Deprivation was
measured by the Carstairs deprivation index (‘DepCat’: an index of
deprivation in a specific postcode).15 During annual follow-up visits in
the trial, further plasma samples were drawn from participants.14
Baseline ECGs
The 12-lead baseline ECGs were obtained by trained nurses using
Siemens Sicard 440 machines and transmitted in digital form to the
ECG Core Laboratory in Glasgow Royal Infirmary. ECGs were inter-
preted using the Glasgow Program16 and separately using an automated
Minnesota Coding program.17 All ECGs were over-read by an experi-
enced reviewer to exclude erroneous interpretations and resolve dis-
crepancies. All study measurements, including ECG, were made blind
to the randomized allocation of study drug. Individuals with Minnesota
codes 1-1, 1-2, 1-3, 4-1, 5-1, 6-4-1, or 7-1-1 on ECG were excluded
from the trial, given that this was a primary prevention study. In addition,
a significant arrhythmia such as atrial fibrillation or AV dissociation was
also an exclusion criterion.14 Minor ST-T abnormalities were defined
as codes 4-2, 4-3 and 5-2, 5-3. Such abnormalities are associated with
an increased risk of coronary heart disease.18
Identification of cardiovascular disease
and mortality endpoints
During the trial, patients were followed for the occurrence of endpoint
events, which were reviewed and classified by an endpoints commit-
tee.13 However, in this report, over a median follow-up of 14.7
years,13 CVD events and mortality endpoints were identified by
linkage to records held by the NHS Scotland. This technique based
on computerized linkage alone can be as effective as reporting based
on direct contact with the patients.19 Data on outcome events were
extracted from the databases with the use of appropriate International
Classification of Diseases codes (versions 9 and 10). Approval for the
extended follow-up was given by an Ethics Committee and by the
Scottish Privacy Advisory Committee. Endpoints were defined as pre-
viously reported20:
(i) Primary endpoint: All CVD events. Composite CVD outcomes
include death from or hospitalization for CHD, non-fatal MI, and
fatal or non-fatal stroke. For the outcomes of MI and stroke, any
record of MI or stroke, whether or not it was the primary
reason for hospitalization, was included as an event. For CHD
events, any event that was the primary reason for hospitalization
(including revascularization procedures and the onset of acute
angina) and any non-fatal MI were recorded as events.13
(ii) Secondary endpoints: The composite CVD primary endpoint was
split according to whether the event was fatal: CVD death (as iden-
tified by the primary cause on the death certificate), or non-fatal
CVD events (excluding fatal events). CHD events and stroke
were reported separately. The CHD endpoint was further split
by fatal and non-fatal outcomes. Non-CVD death was also
reported separately.
All analyses were on a time-to-first-event basis.
Biomarker measurement
Owing to attrition of WOSCOPS blood banks, only one previously
unthawed aliquot of baseline plasma remained in storage, and this
sample was not available to all subjects due to the variable quantities
of blood drawn. Thus, a baseline plasma sample was available in 4801 sub-
jects of 6595 randomized (72.8%). In addition, plasma NT-proBNP was
measured at 1 year in trial in a random sample of 1154 men who also had
their baseline NT-proBNP measured. N-terminal pro-B-type natriuretic
peptide was determined using the Elecsys 2010 electrochemilumines-
cence method (Roche Diagnostics, Burgess Hill, UK). The manufac-
turer’s controls were used to monitor quality control with limits of
acceptability defined by the manufacturer. The low control coefficient
of variation (CV) was 6.3% and high control CV was 5.1%. The limit of
sensitivity was 5 pg/mL. C-reactive protein was measured by a high-
sensitivity two-site enzyme-linked immunoassay. The assay was cali-
brated with a standard (CRM470-CAP/IFCC; lot 91/0619, Behringwerke,
Marburg, Germany). The lower limit of sensitivity of the assay was
0.1 mg/L. The intra-assay and inter-assay coefficients of variation were
1.9 and 6.2%, respectively.11
Statistics
All subjects with available NT-proBNP measures were used in ana-
lyses. We defined a ‘clean CVD cohort’ for sensitivity analyses: this
cohort excluded individuals with ECG codings for minor ST abnormal-
ities (as above), those who had a positive Rose questionnaire for
angina, those who were taking nitrates, or had a history of claudication
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plus or any other type of history of CVD, or had a previous history of
cerebrovascular disease (transient ischaemic attack or stroke). Normal
distributions were approximated by taking logarithms of positively
skewed variables. Comparison of the mean logNT-proBNP (and
logC-reactive protein) between the ‘clean CVD cohort’ and those
not in the clean CVD cohort and between trial treatment arms was
made using the two-sample t-test. Time-to-event curves were calcu-
lated by the Kaplan–Meier method and compared using the log-rank
test for all-cause mortality, and for all CVD events cumulative inci-
dence curves were calculated and compared statistically taking into
account the competing risk of non-CV mortality.21
Associations of C-reactive protein with the risk of CVD events in
WOSCOPS (for the in-trial period only) have been previously
reported.11 Our primary analysis assessed the association of
NT-proBNP with the risk of the primary outcome (composite fatal
and non-fatal CVD events) in the full cohort. Subdistribution hazard
ratios (HRs) (HRs accounting for the competing risk of non-CVD
death) were estimated with 95% CIs for a standard deviation increase
in log NT-proBNP22,23 (Supplementary material online). These esti-
mates are shown for pre-defined models, adjusting for age, treatment,
and other risk factors. In addition, P-values were calculated from the
HR for the associations of NT-proBNP with fatal vs. non-fatal CVD
events compared across subgroups in a cause-specific Cox model
using a x2 test for heterogeneity.24
C-indexes (and 95% CI) were calculated for the primary endpoint
(all CVD events) and for fatal CVD events taking into account the
competing risk of non-CVD death,22 to assess concordance between
model predictions and observed outcomes. We calculated the net re-
classification improvement (NRI) index in the context of competing
risks25 (based on improvements in classification across integer % risk
thresholds), along with a sensitivity analysis based on a categorical
net reclassification across a 10-year 20% risk threshold. Bootstrap
resampling with 999 repetitions was used to calculate 2.5 and 97.5 per-
centiles to approximate the 95% CIs for NRI.
All analyses were performed using Rv2.12.1, adapting the software
and methods of Wolbers,26 and SAS v9.2.
Results
Baseline characteristics
Participants with samples available for the measurement of
NT-proBNP were broadly similar to subjects with missing samples
(Supplementary material online). The geometric mean+ geometric
standard deviation for NT-proBNP and C-reactive protein in the full
cohort was 28+ 61 pg/mL and 1.73+4.60 mg/L, respectively. Of
the 4801 men with NT-proBNP measurements, 4128 were in the
clean CVD cohort; this cohort had a geometric mean NT-proBNP
of 26+54 pg/mL (P ¼ 0.01 compared with those not in the clean
cohort).
Associations of NT-proBNP with classical CVD risk factors
were investigated, and showed broadly expected associations (Sup-
plementary material online). Interestingly, NT-proBNP was also
higher in those more deprived (P ¼ 0.046 vs. least deprived) in
an adjusted model. The presence of angina was strongly associated
with increased NT-proBNP, as was the prescription of beta-
blockers (P, 0.001) and nitrate medication (P, 0.001).
N-terminal pro-B-type natriuretic
peptide associations with the risk of
cardiovascular disease and mortality
events
There was no evidence that baseline NT-proBNP or C-reactive
protein associations with CVD risk were different by treatment al-
location: heterogeneity P-values being P ¼ 0.85, 0.80, and 0.79 for
Figure 1 The cumulative incidence plot relating quarters of the N-terminal pro-B-type natriuretic peptide and C-reactive protein distribu-
tions (as defined in the figure) to all cardiovascular disease.
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total CVD, fatal CVD, and non-fatal CVD events, respectively, for
NT pro-BNP, and P ¼ 0.73, P ¼ 0.95, and P ¼ 0.51, respectively,
for C-reactive protein.
Over a median of 14.7 years of follow-up, there were a total of
1690 fatal and non-fatal CVD events and 856 deaths among the
4801 men. Time-to-event and cumulative incidence curves across
quarters of the distribution of baseline C-reactive protein and
NT-proBNP are given in Figures 1 and 2; there was evidence of
an increased risk of CVD and all-cause mortality with higher
NT-proBNP levels (P, 0.001 for both).
Associations of NT-proBNP with the risk of CVD events and all-
cause mortality were analysed both in the whole cohort, and in the
clean CVD cohort (Table 1). In the full cohort, the HR was 1.17
(95% CI: 1.11–1.23) for a standard deviation increase in log
NT-proBNP for all CVD events after adjusting for classical and
clinical cardiovascular risk factors plus C-reactive protein. N-ter-
minal pro-B-type natriuretic peptide was associated with the fatal
CVD endpoint more strongly than with non-fatal CVD (P for inter-
action ¼ 0.022).
Restricting analyses to the clean CVD cohort made little material
difference to the strength of risk associations, although the associ-
ation of NT-proBNP to non-fatal CHD events in the fully adjusted
model was attenuated from borderline to non-significance.
N-terminal pro-B-type natriuretic
peptide and prediction of cardiovascular
disease events
C-index changes for the addition of NT-proBNP or C-reactive
protein to traditional risk models for all CVD (n ¼ 1690) and
fatal CVD events (n ¼ 345) were investigated (Table 2). The
C-index for the traditional risk factor model improved by
+0.013 with the addition of NT-proBNP and +0.009 with the
addition of C-reactive protein. Incremental discrimination yielded
from inclusion of NT-proBNP and C-reactive protein into the
fatal CVD model was superior to comparable gains made in the
total CVD model (Table 2). For both fatal and non-fatal CVD
models, NT-proBNP and C-reactive protein added independent
discriminative ability. Similar improvements in discrimination
were seen when analyses were restricted to the clean CVD
cohort (Table 2).
Using a continuous NRI, NT-proBNP correctly reclassified
14.7% of events and 5.1% of non-events, compared with 3.4 and
6.4%, respectively, for C-reactive protein (Table 3). As a sensitivity
analysis, we also assessed the reclassification achieved by
NT-proBNP and C-reactive protein using a binary categorical
model of reclassification across a 20% 10-year risk threshold for
all CVD events. The net gain for adding NT-proBNP was 2.2%
(95% CI: 1.2–3.1%), whereas the net gain for adding C-reactive
protein was 1.0% (95% CI: 0.2–1.8%).
N-terminal pro-B-type natriuretic
peptide following statin treatment
N-terminal pro-B-type natriuretic peptide was also measured at
1 year in trial in a random sample of 1154 men for whom baseline
NT-proBNP was available. After 1 year of statin treatment, the
geometric mean follow-up NT-proBNP was no different in the
statin group (24.7+60.6 pg/mL) compared with placebo
(25.2+58.0 pg/mL) in unadjusted analysis (P ¼ 0.70) or in analysis
adjusted for baseline NT-proBNP (P ¼ 0.57). N-terminal pro-B-
Figure 2 The time-to-event plot relating quarters of the N-terminal pro-B-type natriuretic peptide and C-reactive protein distributions (as
defined in the figure) to all-cause mortality.
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Table 2 C-index of risk factors for 14.7 year cardiovascular disease outcomes (and fatal only outcomes) in both the full
cohort and the cohort without evidence of cardiovascular disease (after accounting for competing risk of
non-cardiovascular disease death)
All CVD events Fatal CVD events only
C index (95% CI) P-value* C index (95% CI) P-value*
Full cohort
Traditionala 0.587 (0.58–0.60) — 0.684 (0.65–0.71) —
Traditional and C-reactive protein 0.596 (0.58–0.61) ,0.001 0.701 (0.67–0.73) ,0.001
Traditional and NT-proBNP 0.600 (0.59–0.61) ,0.001 0.705 (0.68–0.73) ,0.001
Traditional, C-reactive protein and NT-proBNP 0.606 (0.59–0.62) ,0.001 0.719 (0.69–0.75) ,0.001
Clean CVD cohort
Traditionala 0.582 (0.57–0.60) — 0.698 (0.67–0.73) —
Traditional and C-reactive protein 0.588 (0.57–0.60) ,0.001 0.708 (0.67–0.75) ,0.001
Traditional and NT-proBNP 0.594 (0.58–0.61) ,0.001 0.710 (0.68–0.74) ,0.001
Traditional, C-reactive protein, and NT-proBNP 0.599 (0.59–0.61) ,0.001 0.719 (0.69–0.75) ,0.001
aTraditional risk factors include randomized treatment, age, smoking status, systolic blood pressure, high-density lipoprotein, total cholesterol, and diabetes.
*Comparisons with the traditional model.
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Table 1 Associations for 1 SD increase in log N-terminal pro-B-type natriuretic peptide for cardiovascular disease
endpoints and mortality, taking account of the competing risk of non-CVD death
Event Model Full cohort, sHR
(95% CI) P-value
Clean cohorta, sHR
(95% CI) P-value
All CVD events
All CVD events, full: n ¼ 1690 (35.20%), clean: n ¼ 1357 (32.87%) Model 1 1.22 (1.16–1.29) ,0.001 1.20 (1.13–1.27) ,0.001
Model 2 1.17 (1.11–1.23) ,0.001 1.17 (1.10–1.24) ,0.001
All CHD events, full: n ¼ 1002 (20.87%), clean: n ¼ 779 (18.87%) Model 1 1.17 (1.09–1.25) ,0.001 1.10 (1.02–1.19) 0.01
Model 2 1.09 (1.02–1.17) 0.01 1.06 (0.98–1.15) 0.13
Stroke NF/F events, full: n ¼ 292 (6.08%), clean: n ¼ 220 (5.33%) Model 1 1.35 (1.18–1.53) ,0.001 1.33 (1.15–1.54) ,0.001
Model 2 1.22 (1.07–1.39) ,0.01 1.23 (1.06–1.42) ,0.01
Non-fatal CVD events
NF CVD, full: n ¼ 1532 (31.91%), clean: n ¼ 1232 (29.84%) Model 1 1.21 (1.15–1.28) ,0.001 1.19 (1.12–1.26) ,0.001
Model 2 1.17 (1.10–1.24) ,0.001 1.17 (1.10–1.24) ,0.001
NF CHD, full: n ¼ 853 (17.77%), clean: n ¼ 661 (16.01%) Model 1 1.13 (1.05–1.22) 0.001 1.07 (0.99–1.16) 0.09
Model 2 1.07 (1.00–1.16) 0.06 1.05 (0.96–1.14) 0.29
Fatal events
CVD death, full: n ¼ 345 (7.19%), clean: n ¼ 253 (6.13%) Model 1 1.47 (1.31–1.65) ,0.001 1.40 (1.22–1.61) ,0.001
Model 2 1.34 (1.19–1.52) ,0.001 1.29 (1.11–1.48) 0.001
CHD death, full: n ¼ 233 (4.85%), clean: n ¼ 171 (4.14%) Model 1 1.46 (1.27–1.67) ,0.001 1.34 (1.13–1.58) 0.001
Model 2 1.33 (1.15–1.54) ,0.001 1.22 (1.03–1.45) 0.02
Non-CV death, full: n ¼ 522 (10.87%), clean: n ¼ 428 (10.37%) Model 1 1.13 (1.03–1.24) ,0.01 1.15 (1.04–1.27) ,0.01
Model 2 1.09 (1.00–1.20) 0.06 1.12 (1.00–1.24) 0.04
HR, hazard ratio; NF, non-fatal; F, fatal.
Model 1: adjusted for randomized treatment and age.
Model 2: in addition to Model 1, adjusted for BMI, smoking, diabetes, systolic blood pressure, hypertension, HDL and LDL cholesterol, triglycerides, nitrate use, history of angina,
social deprivation score (DEPCAT), various medications (aspirin, ACE-inhibitors, beta-blockers, calcium channel blockers, diuretics, others), and C-reactive protein.
aClean CVD cohort: patients with positive Rose angina, stroke/TIA, ECG abnormalities, claudication and history of another type of vascular disease were excluded.
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type natriuretic peptide was hence unaffected by 1 year of statin
treatment.
Discussion
WOSCOPS provides a valuable platform to evaluate the usefulness
of NT-proBNP in CVD risk prediction. We show that when added
to conventional risk factors, NT-proBNP provides around double
the incremental gain for the prediction of CVD compared with
C-reactive protein. We report that this predictive capacity
remains broadly unchanged when the cohort is restricted to
those without evidence of pre-existing angina, claudication,
minor ECG abnormalities, or previous stroke. In addition, we
show for the first time that NT-proBNP appears more strongly
associated to the risk of fatal compared with non-fatal CVD
events, and that NT-proBNP is higher in those from poorer socio-
economic groups. In so doing, our results provide further support
to consider the wider use of NT-proBNP in CVD risk prediction.
History of previous vascular events is one of the most important
risk factors for future vascular events.27 Given that natriuretic pep-
tides are sensitive and continuous markers of both clinically appar-
ent and subclinical ischaemia,2 –4 it is perhaps unsurprising that high
circulating concentrations of natriuretic peptides are associated
with CVD.1 We have excluded major cardiovascular abnormalities
as a mediator between NT-proBNP and CVD risk. It is possible
that more subtle underlying baseline ECG abnormalities which
were of minimal prevalence, such as minor arrhythmias, were
related to both NT-proBNP and the risk of future CVD.
However, our findings suggest that NT-proBNP levels do not
merely reflect clinically identifiable CVD, but that levels also indi-
cate a vascular risk even when well within the traditionally
‘normal’ range. Therefore NT-proBNP appears to offer the poten-
tial to enhance CVD risk assessment in a primary prevention
setting, a finding deserving of urgent further investigation.
Our results suggest that NT-proBNP could be more closely
aligned to the risk of CVD death than non-fatal CVD events.
We have previously shown that the inflammatory markers IL-6
and C-reactive protein are more closely aligned to the risk of
CVD death than non-fatal events in the PROSPER study.24 Al-
though the mechanism for this finding is unclear, one of the re-
search implications of this is that studies reporting only fatal
CVD events are likely to report stronger risk associations than
studies reporting a combined fatal and non-fatal endpoint.
Although the discrimination of total CVD events using tradition-
al risk factors was weaker in WOSCOPS than in other cohorts
[due in part to the narrow age range (45–65), inclusion of males
only and a narrow LDL-cholesterol range], we find that
NT-proBNP offers potentially useful improvement in discrimin-
ation, even when individuals with minor (as well as major)
cardiac abnormalities were excluded. This finding is broadly in
agreement with other recent findings in healthy elderly men,28
and thus has some evidence of external validity.
NT-proBNP is currently a more expensive test than C-reactive
protein, but as the clinical use of the test increases, costs are likely
to decline. As with all circulating biomarkers, financial as well as dis-
criminatory benefit would have to be demonstrated before these
tests are considered for integration into existing risk scores.29 Our
results therefore also advance the case for examining the cost-
effectiveness of NT-proBNP for CVD risk prediction in due course.
Strengths and limitations
WOSCOPS is a powerful primary prevention study to assess the
predictive value of NT-proBNP in CVD. Restriction of the trial
to healthy middle-aged men with hypercholesterolaemia limits
the generalizability of the study although our results for both NT
proBNP and C-reactive protein appear externally consistent with
other cohorts of healthy men without hypercholesterolaemia.28
Our results are also consistent with other studies in showing the
potential for NT-proBNP to offer greater discriminative
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Table 3 Reclassificationmetrics for 14.7-year risk of all cardiovascular disease outcomes in both the full cohort, and the
cohort without evidence of cardiovascular disease (after accounting for competing risk of non-cardiovascular disease
death)
Continuous NRI
Total NRIa (95% CI) Event NRI (%) Non-event NRI (%)
Full cohort
Traditionalb + C-reactive protein +9.8% (4.2 to 15.6%) +3.4 +6.4
Traditional + NT-proBNP +19.8% (13.6 to 25.9%) +14.7 +5.1
Traditional + C-reactive protein + NT-proBNP 19.3% (12.7 to 25.4%) +9.3 +10.0
Clean CVD cohort
Traditionalb + C-reactive protein +6.5% (20.1 to 12.9%) +1.7 +4.8
Traditional + NT-proBNP +17.3% (11.0 to 24.0%) +13.5 +3.7
Traditional + C-reactive protein + NT-proBNP +17.7% (11.2 to 24.2%) +9.9 +7.7
NRI, net reclassification index; IDI, integrated discrimination index.
aContinuous NRI based on improvements across integer % thresholds for .0% risk.
bTraditional risk factors include randomized treatment, age, smoking status, systolic blood pressure, high density lipoprotein, total cholesterol, and diabetes.
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information than C-reactive protein.5,28 The issue of generalizabil-
ity is likely be addressed by future meta-analyses. The samples used
to measure NT-proBNP have been in storage since 1989–91.
These were samples that had not been utilized for biomarker
measurement previously and the concentrations of NT-proBNP
detected are clinically credible for a healthy middle-aged cohort.
N-terminal pro-B-type natriuretic peptide levels between baseline
and 2-years in frozen storage correlate extremely well.30 In add-
ition, very few cases (or indeed non-cases) in this cohort had
,20% 10-year risk for all CVD events; thus our results generated
using a categorical model of reclassification may underestimate the
utility of both biomarkers for the prediction of CVD. The use of a
continuous NRI partially circumvents this issue. We did not utilize
repeat measures of NT-proBNP to yield a regression dilution esti-
mate because NT-proBNP expression by the myocardium is a
dynamic response to underlying cardiac stress, and not a causal
agent or therapeutic target. We are interested in the prognostic
value of a single measure of NT-proBNP; thus regression dilution
estimates are not necessarily relevant in this case.
Conclusion
In conclusion, we show that NT-proBNP predicts CVD events (fatal
more strongly than non-fatal events) in middle-aged men without
clinical evidence of CHD, angina, or history of stroke. N-terminal
pro-B-type natriuretic peptide also enhances risk discrimination
beyond traditional risk predictions, and does so better than
C-reactive protein. Consequently, further work investigating the
use of NT proBNP in CVD risk scores, including examining its cost-
effectiveness, deserves urgent consideration.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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Echocardiographic particle image velocimetry in a patient with severe
diastolic dysfunction
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Particle image velocimetry (PIV echocardiog-
raphy; software: Hyper Floww, version 6.0.2.0),
applied to contrast-enhanced echocardiographic
images, is a new technique to display and quan-
tify blood flow velocity and direction and allows
new insights into typical cardiac blood flow pat-
terns, such as vortices. A vortex is a mass of fluid
with a circular motion containing kinetic energy.
The growing knowledge about the structure
and function of the left ventricle (LV) was of
high interest to us in the context of ventricular
vortex development in patients with diastolic
dysfunction. Vortex structures are supposed to
increase cardiac efficiency by maintaining the
momentum of the inflowing blood in diastole
and, thus, facilitating systolic ejection of blood
into the LV outflow tract. The demonstration
of diastolic vortex formation in normal human
hearts led to our study objective to what
extent blood flow patterns in diastolic dysfunc-
tion are different from normal ones.
The figure demonstrates the comparison of the two-dimensional apical four-chamber view and location and morphology of the
average left ventricular vortex flow pattern between a normal individual and a patient with hypertrophic cardiomyopathy with
severe diastolic dysfunction. The centre of the average vortex flow was located near the apex in the normal. However, in the
patient with diastolic dysfunction, more chaotic flow patterns could be observed without clear vortex formation, indicating a disturbed
haemodynamic during diastole. The colour coded flow data represent a positive vorticity with a counterclockwise rotation of the
blood (red). The blue colour represents negative vorticity with clockwise rotation.
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